Background

Philipp is an infectious diseases specialist with more than 15 years of extensive clinical and public health experience, and over 10 years’ experience in the management of TB/HIV programs. He has worked as a TB/HIV advisor, and supported program implementation and research in a range of settings. He has worked with MDR TB programs across Tajikistan, Uzbekistan, India, Myanmar, Uganda, Swaziland and Zimbabwe.

Philipp’s work has a strong focus on research, in particular in the development of shorter treatment regimens for MDR TB, as head of the Manson Unit at Médecins Sans Frontières in the United Kingdom from 2010 to 2017.

In addition Philipp is an expert member of both the WHO Guidelines Development Group for Isoniazid Resistant TB Guidelines, and the European Research Initiative for Tuberculosis.

Philipp joins Burnet Institute as an Infectious Diseases Specialist in the TB Elimination and Implementation Science working group, supporting program implementation and research activities.

Appointments

• Member of the Guidelines Development Group for Isoniazid Resistant Tuberculosis Guidelines 2017, World Health Organization
• Member of the European Research Initiative for Tuberculosis (ERI-TB), World Health Organization
• Adviser MSF Global Health and Humanitarian Medicine Course
• Fellow of the Royal Australasian College of Physicians – Infectious Diseases Specialist
• Fellow of the Australasian College of Tropical Medicine
• Honorary Consultant, Monash Medical Centre, Melbourne Australia 2014
• Honorary Clinical Fellow (Infectious Diseases), Imperial College 2010 – 2011
• Member Australasian Society of Infectious Diseases
• Member Australasian Society of HIV Medicine

Positions

2017: Research Adviser / Course Director MSF Global Health and Humanitarian Medicine Course Médecins Sans Frontières UK
2010-2017: Head of the Manson Unit / TB-HIV Adviser Médecins Sans Frontières UK
2008-2010: Tuberculosis Program Implementer, Manson Unit, Médecins Sans Frontières
2007-2008: Infectious diseases doctor, HIV Programme Lagos, Nigeria, Médecins Sans Frontières
2006-2007: Physician, Perth Chest (Tuberculosis) Clinic 2005-2006: Planning Coordinator for Monitoring and Evaluation of Malaysian National Needle Syringe Exchange Program Pilot
2005: Interim Country Medical Coordinator, Merlin (Medical Emergency Relief International) Tajikistan
2005: Consultant Specialist, The Alfred Hospital Travel Medicine Clinic
2004-2005: Clinical Adviser for National HIV Training Curriculum, Australasian Society of HIV Medicine
2002-2004: Infectious Diseases Registrar, The Alfred Hospital
2004: Facilitator, Antiretroviral Train the Trainer Program, India
1998-2002: Medical Registrar, The Alfred Hospital, North West Regional Hospital, Royal Perth Hospital, Kalgoorlie Hospital
1999: Doctor, Médecins Sans Frontières, Mae Sot Thailand
1996-1998: Resident Medical Officer, Royal Perth Hospital

Qualifications

2006: Masters of Clinical Epidemiology – Monash University
2004: Fellow of the Royal Australasian College of Physicians – Infectious Diseases Specialist
1995: Bachelor of Medicine, Bachelor of Surgery, MBBS University of Western Australia

Projects (2)

Current (2)

• RID-TB: Reducing the Impact of Drug-Resistant TB in Western Province, PNG
  The project supports an effective provincial program to reduce the impact of TB in Daru.
• Zero TB initiative Yogyakarta
  Implementation of a comprehensive Zero TB approach to Tuberculosis control in Yogyakarta, Indonesia

Publications (55)

2019 (4)

• Telemedicine in resource-limited settings to optimize care for multidrug-resistant tuberculosis.
  Huang GKL, Pawape G, Taune M, Hiasihri S, Ustero P, O'Brien DP, du Cros P, Graham S, Wootton R, Majumdar S
  Frontiers in Public Health. 2019 Aug; 7:222
• Training for Tuberculosis Elimination in Indonesia: Achievements, Reflections, and Potential for Impact.
  Main S, Lestari T, Triasih R, Chan G, Davidson L, Majumdar S, Santoso D, Phung S, Laukkala J, Graham S, du Cros P, Ralph A
  Trop Med Infect Dis. 2019 Jul; 4(3):E107
• Bedaquiline overdose: A case report.
  Telnov O, Alvarez V, Gragila E, Molfino L, du Cros P, Rich M
  Int J Infect Dis. 2019 Jul; 84:138-140
• Treatment outcomes of patients switching from an injectable drug to bedaquiline during short standardized MDR-TB treatment in Mozambique.
  Bastard M, Molfino L, Mutaquiha C, Galindo MA, Zindoga P, Vaz D, Mahinça I, du Cros P, Rusch B, Telnov A
  Clin Infect Dis. 2019 Mar; Epub ahead of print

2017 (3)

• Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis.
  Achar J, Hewison C, Cavalheiro AP, Skrahina A, Cajazeiro J, Nargiza P, Herboczek K, Rajabov AS, Hughes J, Ferlazzo G, Seddon JA, du Cros P
  Emerg Infect Dis. 2017 Oct; 23(10):1711-1713
• Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses.
  Ahmad Khan F, Salim MAH, du Cros P, Casas EC, Khamraev A, Sikhondze W, Benedetti A, Bastos M, Lan Z, Jaramillo E, Falzon D, Menzies D
  Eur Respir J. 2017 Jul; Epub ahead of print
• Peripheral neuropathy in a diabetic child treated with linezolid for multidrug-resistant tuberculosis: a case report and review of the literature.
  Swaminathan A, du Cros P, Seddon JA, Mirgayosieva S, Asladdin R, Dusmatova Z
  BMC Infect Dis. 2017 Jun; 17(1):417

2016 (10)

• Modelling the effect of short-course multidrug-resistant tuberculosis treatment in Karakalpakstan, Uzbekistan.
  Trauer JM, Achar J, Parpieva N, Khamraev A, Denholm JT, Falzon D, Jaramillo E, Mesic A, du Cros P, McBryde ES
  BMC Med. 2016 Nov; 14(1):187
• WHO recommendations for multidrug-resistant tuberculosis.
  Catherine Berry, Jay Achar, Philipp du Cros
  Lancet. 2016 Nov; 388(10057):2234
• 'They prefer hidden treatment': anti-tuberculosis drug-taking practices and drug regulation in Karakalpakstan.
  B Stringer, K Lowton, M Tillashaikhov, N Parpieva, D Ulmasova, P du Cros, E Hasker, N Sergeeva
  Int J Tuberc Lung Dis. 2016 Aug; 20(8):1084-1090
• Where there is hope: a qualitative study examining patients' adherence to multi-drug resistant tuberculosis treatment in Karakalpakstan, Uzbekistan.
  Shona Horter, Beverley Stringer, Jane Greig, Akhmet Amangeldiev, Mirzagaleb N Tillashaikhov, Nargiza Parpieva, Zinaida Tigay, Philipp du Cros
  BMC Infect Dis. 2016 Jul; 16:362
• Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China.
  Catherine Berry, Tom A Yates, James A Seddon, Patrick P J Phillips, Philipp du Cros
  Eur Respir J. 2016 May; 47(5):1591-1592
• Treating children for drug-resistant tuberculosis in Tajikistan with Group 5 medications.
  A Swaminathan, P du Cros, J A Seddon, S Quinnell, O I Bobokhojaev, Z Dusmatova, J Achar
  Int J Tuberc Lung Dis. 2016 Apr; 20(4):474-478
• Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults.
  J Furin, E Alirol, E Allen, K Fielding, C Merle, I Abubakar, J Andersen, G Davies, K Dheda, A Diacon, K E Dooley, G Dravnice, K Eisenach, D Everitt, D Ferstenberg, A Goolam-Mahomed, M P Grobusch, R Gupta, E Harausz, M Harrington, C R Horsburgh, C Lienhardt, D McNeeley, C D Mitnick, S Nachman, P Nahid, A J Nunn, P Phillips, C Rodriguez, S Shah, C Wells, B Thomas-Nyang'wa, P du Cros
  Int J Tuberc Lung Dis. 2016 Mar; 20(3):290-294
• Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study.
  M Bonnet, M Bastard, P du Cros, A Khamraev, K Kimenye, S Khurkhumal, A Hayrapetyan, D Themba, A Telnov, E Sanchez-Padilla, C Hewison, F Varaine
  Int J Tuberc Lung Dis. 2016 Feb; 20(2):177-186
• Risk factors for mortality during antiretroviral therapy in older populations in resource-limited settings.
  O'Brien D, Spelman T, Greig J, McMahon J, Ssonko C, Casas E, Mesic A, Du Cros P, Ford N
  J Int AIDS Soc. 2016 Jan; 19(1):20665
• Barriers to new drug development in respiratory disease.
  Grania Brigden, Philipp du Cros, Sidney Wong
  Eur Respir J. 2016 Jan; 47(1):356-357

2015 (8)

• Progress in Medicine: Experts Take Stock.
  Andrew Beck, Ewan Birney, Manuel Graeber, James Tumwine, Phillipa Hay, Hyeong Sik Ahn, Anushka Patel, Philipp du Cros, Lorenz von Seidlein, Nick Wareham, Nicola Low
  PLoS Med. 2015 Dec; 12(12):e1001933
• A bitter pill to swallow: the need for better medications for drug-resistant tuberculosis in children.
  J Furin, A Mafukidze, G Brigden, P du Cros, R Golin, E Harausz, J A Seddon, P Ustero, A J Garcia-Prats
  Int J Tuberc Lung Dis. 2015 Dec; 19(12):55-60
• Generating Evidence to Improve the Response to Neglected Diseases: How Operational Research in a Medecins Sans Frontieres Buruli Ulcer Treatment Programme Informed International Management Guidance.
  Daniel P O'Brien, Nathan Ford, Marco Vitoria, Kingsley Asiedu, Alexandra Calmy, Philipp Du Cros, Eric Comte, Vanessa Christinet
  PLoS Negl Trop Dis. 2015 Nov; 9(11):e0004075
• Multidrug-Resistant Tuberculosis in Child Successfully Treated with 9-Month Drug Regimen.
  Jay Achar, Catherine Berry, Krzysztof Herboczek, Nargiza Parpieva, Mirzagaleb N Tillyashaykhov, Zinaida N Tigay, Atadjan Khamraev, Kalyan Velivela, James A Seddon, Philipp du Cros
  Emerg Infect Dis. 2015 Nov; 21(11):2105-2106
• Reply: How Do the New Definitions for Multidrug-Resistant Tuberculosis Treatment Outcomes Really Perform?
  Mathieu Bastard, Maryline Bonnet, Philipp du Cros, Atadjan Karimovich Khamraev, Armen Hayrapetyan, Kamene Kimenye, Shazina Khurkhumal, Themba Dlamini, Alex Telnov, Elisabeth Sanchez-Padilla, Cathy Hewison, Francis Varaine
  Am J Respir Crit Care Med. 2015 Jul; 192(1):117-118
• Hepatitis C seroprevalence and HIV co-infection in sub-Saharan Africa: a systematic review and meta-analysis.
  V Bhargavi Rao, Nur Johari, Philipp du Cros, Janey Messina, Nathan Ford, Graham S Cooke
  Lancet Infect Dis. 2015 Jul; 15(7):819-824
• Challenges and solutions to implementing drug-resistant tuberculosis programmes for children in Central Asia.
  P du Cros, A Swaminathan, O I Bobokhojaev, Z D Sharifovna, C Martin, K Herboczek, C Hohn, J A Seddon
  Public Health Action. 2015 Jun; 5(2):99-102
• Revised definitions of multidrug-resistant tuberculosis treatment outcomes: closer to the reality?
  Mathieu Bastard, Maryline Bonnet, Philipp du Cros, Atadjan Karimovich Khamraev, Armen Hayrapetyan, Kamene Kimenye, Shazina Khurkhumal, Themba Dlamini, Alex Telnov, Elisabeth Sanchez-Padilla, Cathy Hewison, Francis Varaine
  Am J Respir Crit Care Med. 2015 Feb; 191(3):355-358

2014 (5)

• "I can also serve as an inspiration": a qualitative study of the TB&Me blogging experience and its role in MDR-TB treatment.
  Shona Horter, Beverley Stringer, Sarah Venis, Philipp du Cros
  PLoS One. 2014 Sep; 9(9):e108591
• Moxifloxacin for Buruli ulcer/HIV-coinfected patients: kill two birds with one stone? Author reply.
  Daniel P O'Brien, Eric Comte, Nathan Ford, Vanessa Christinet, Philipp Du Cros
  AIDS. 2014 Jul; 28(12):1845-1846
• The urgent need for clinical, diagnostic, and operational research for management of Buruli ulcer in Africa.
  Daniel P O'Brien, Eric Comte, Micaela Serafini, Genevieve Ehounou, Annick Antierens, Hubert Vuagnat, Vanessa Christinet, Mitima D Hamani, Philipp du Cros
  Lancet Infect Dis. 2014 May; 14(5):435-440
• "Home is where the patient is": a qualitative analysis of a patient-centred model of care for multi-drug resistant tuberculosis.
  Shona Horter, Beverley Stringer, Lucy Reynolds, Muhammad Shoaib, Samuel Kasozi, Esther C Casas, Meggy Verputten, Philipp du Cros
  BMC Health Serv Res. 2014 Feb; 14:81
• Principles for designing future regimens for multidrug-resistant tuberculosis.
  Grania Brigden, Bern-Thomas Nyang'wa, Philipp du Cros, Francis Varaine, Jennifer Hughes, Michael Rich, C Robert Jr Horsburgh, Carole D Mitnick, Eric Nuermberger, Helen McIlleron, Patrick P J Phillips, Manica Balasegaram
  Bull World Health Organ. 2014 Jan; 92(1):68-74

2013 (11)

• Towards the WHO target of zero childhood tuberculosis deaths: an analysis of mortality in 13 locations in Africa and Asia.
  G K Russell, C S Merle, G S Cooke, E C Casas, M Silveira da Fonseca, P du Cros
  Int J Tuberc Lung Dis. 2013 Dec; 17(12):1518-1523
• Risk factors associated with default from multi- and extensively drug-resistant tuberculosis treatment, Uzbekistan: a retrospective cohort analysis.
  Maeve K Lalor, Jane Greig, Sholpan Allamuratova, Sandy Althomsons, Zinaida Tigay, Atadjan Khaemraev, Kai Braker, Oleksander Telnov, Philipp du Cros
  PLoS One. 2013 Nov; 8(11):e78364
• Should mortality data for the elderly be collected routinely in emergencies? The practical challenges of age-disaggregated surveillance systems.
  Philipp du Cros, Sarah Venis, Unni Karunakara
  Trans R Soc Trop Med Hyg. 2013 Nov; 107(11):669-671
• Multidrug-resistant tuberculosis in Uzbekistan: results of a nationwide survey, 2010 to 2011.
  D J Ulmasova, G Uzakova, M N Tillyashayhov, L Turaev, W van Gemert, H Hoffmann, M Zignol, K Kremer, T Gombogaram, J Gadoev, P du Cros, N Muslimova, A Jalolov, A Dadu, P de Colombani, O Telnov, A Slizkiy, B Kholikulov, M Dara, D Falzon
  Euro Surveill. 2013 Oct; 18(42)
• Moxifloxacin for Buruli ulcer/HIV coinfected patients: kill two birds with one stone?
  Daniel P O'Brien, Eric Comte, Nathan Ford, Vanessa Christinet, Philipp du Cros
  AIDS. 2013 Sep; 27(14):2177-2179
• Viral hepatitis and the Global Burden of Disease: a need to regroup.
  G S Cooke, M Lemoine, M Thursz, C Gore, T Swan, A Kamarulzaman, P Du Cros, N Ford
  J Viral Hepat. 2013 Sep; 20(9):600-601
• Predictors of Raised Viral Load during Antiretroviral Therapy in Patients with and without Prior Antiretroviral Use: A Cross-Sectional Study.
  Greig JE, du Cros PA, Mills C, Ugwoeruchukwu W, Etsetowaghan A, Grillo A, Tayo-Adetoro A, Omiyale K, Spelman T, O'Brien DP
  PLoS One. 2013 Aug; 8(8):e71407
• Impact of HIV-associated conditions on mortality in people commencing anti-retroviral therapy in resource limited settings.
  Marshall CS, Curtis AJ, Spelman T, O'Brien DP, Greig J, Shanks L, du Cros P, Casas EC, da Fonseca MS, Athan E, Elliott JH
  PLoS One. 2013 Jul; 8(7):e68445
• Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis.
  A Toczek, H Cox, P du Cros, G Cooke, N Ford
  Int J Tuberc Lung Dis. 2013 Mar; 17(3):299-307
• Resistance to second-line drugs in multidrug-resistant tuberculosis.
  Bern-Thomas Nyang'wa, Grania Brigden, Philipp du Cros, Leslie Shanks
  Lancet. 2013 Feb; 381(9867):625
• Treatment outcomes of treatment-naive Hepatitis C patients co-infected with HIV: a systematic review and meta-analysis of observational cohorts.
  Anna Davies, Kasha P Singh, Zara Shubber, Philipp du Cros, Edward J Mills, Graham Cooke, Nathan Ford
  PLoS One. 2013 Feb; 8(2):e55373

2012 (6)

• Incidence of WHO Stage 3 and 4 Conditions following Initiation of Anti-Retroviral Therapy in Resource Limited Settings.
  Curtis AJ, Marshall CS, Spelman T, Greig J, Elliot JH, Shanks L, Du Cros P, Casas EC, Da Fonseca MS, O'Brien DP
  PLoS One. 2012 Dec; 7(12):e52019
• Public health advocacy for the Berlin Declaration on tuberculosis in the former Soviet Union: The view of Medecins Sans Frontieres.
  S Healy, S Dietrich, T Roth, B-T Nyang'wa, P du Cros
  Eur J Microbiol Immunol (Bp). 2012 Dec; 2(4):282-286
• HIV replication is associated with increased severity of liver biopsy changes in HIV-HBV and HIV-HCV co-infection.
  Audsley J, du Cros P, Goodman Z, McLean C, Mijch A, Lewin SR, Sasadeusz J
  J Med Virol. 2012 Jul; 84(7):993-1001
• Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis.
  Nathan Ford, Catherine Kirby, Kasha Singh, Edward J Mills, Graham Cooke, Adeeba Kamarulzaman, Philipp du Cros
  Bull World Health Organ. 2012 Jul; 90(7):540-550
• Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS.
  Nathan Ford, Kasha Singh, Graham S Cooke, Edward J Mills, Tido von Schoen-Angerer, Adeeba Kamarulzaman, Philipp du Cros
  Clin Infect Dis. 2012 May; 54(10):1465-1472
• Association of BMI category change with TB treatment mortality in HIV-positive smear-negative and extrapulmonary TB patients in Myanmar and Zimbabwe.
  Lenka Benova, Katherine Fielding, Jane Greig, Bern-Thomas Nyang'wa, Esther Carrillo Casas, Marcio Silveira da Fonseca, Philipp du Cros
  PLoS One. 2012 Apr; 7(4):e35948

2011 (4)

• Counting children: comparing reporting for paediatric HIV and tuberculosis.
  Philipp du Cros, Bern-Thomas Nyang'wa, Marianne Gale, Sarah Venis, Nathan Ford
  Bull World Health Organ. 2011 Dec; 89(12):855
• The 'frozen state' of drug-resistant tuberculosis: notes from the field in Abkhazia.
  S Majumdar, D O'Brien, N Hurtado, C Hewison, P du Cros
  Intern Med J. 2011 Dec; 41(12):805-808
• Drug-resistant tuberculosis in 9 high burden Asian countries. (Report)
  Majumdar S, Kong F, du Cros P, O’Brien D, Reeder J, Elliott J
  AusAID Health Resource Facility. Australian Government, Canberra. 2011 Jul
• Viral load testing in a resource-limited setting: quality control is critical.
  Jane Greig, Philipp du Cros, Derryck Klarkowski, Clair Mills, Steffen Jorgensen, P Richard Harrigan, Daniel P O'Brien
  J Int AIDS Soc. 2011 May; 14:23

2007 (1)

• Rapid differentiation of Candida albicans from non-albicans species by germ tube test directly from BacTAlert blood culture bottles.
  Jolanta A Terlecka, Philipp A du Cros, C Orla Morrissey, Denis Spelman
  Mycoses. 2007 Jan; 50(1):48-51

2006 (2)

• Successful treatment and cerebrospinal fluid penetration of oral linezolid in a patient with coagulase-negative Staphylococcus ventriculitis.
  Lauren M Boak, Jian Li, Denis Spelman, Philipp du Cros, Roger L Nation, Craig R Rayner
  Ann Pharmacother. 2006 Jul; 40(7-8):1451-1455
• HIV and Tuberculosis Coinfection (Book Chapter)
  du Cros P, Kamanrulzaman A
  in "Delivering HIV Care and Treatment for people who use drugs: lessons from research and practice.". 2006 Jun; Ed. Matt Curtis Open Society Institute New York:pages 111-134

2004 (1)

• Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility.
  Benjamin P Howden, Peter B Ward, Patrick G P Charles, Tony M Korman, Andrew Fuller, Philipp du Cros, Elizabeth A Grabsch, Sally A Roberts, Jenny Robson, Kerry Read, Narin Bak, James Hurley, Paul D R Johnson, Arthur J Morris, Barrie C Mayall, M Lindsay Grayson
  Clin Infect Dis. 2004 Feb; 38(4):521-528

News Articles (13)

2019 (6)

• TB diagnostic trial a potential lifesaver
• Bold strategies map out tuberculosis-free future
• Federal funding boost to address ‘superbugs’ in Asia-Pacific
• ‘It’s time to end TB’
• Focus on research to eliminate TB
• Forging closer TB ties with PNG

2018 (6)

• Creative approaches to TB elimination
• United Nations' commitment to end TB welcomed
• Prestigious physicians' award for Burnet TB researcher
• Addressing TB in Indonesia
• TB elimination course for Indonesian health workers
• Research focus to address TB 'global crisis'

2017 (1)

• New frontiers for TB specialist